)
Expertise
Leader in Research
We are known as a biotechnology leader with a dynamic portfolio of lifesaving products and a reputation for always putting patients first. While biotechnology is still in its early days, we recognize the tremendous potential for a wide range of serious and life-threatening diseases. Every day, we strive to meet commitments and exceed expectations. Headquartered in Melbourne Australia, CSL Limited includes CSL Behring, incorporating CSL Plasma and Seqirus, incorporating Immunohematology.
-
US$832 million
was invested in R&D in 2018/19
-
US$3.3B
in R&D investments in last 5 years
-
>1,700
research & development employees
Areas of Expertise
Biotechnology is a fast-growing field with huge potential, and our two core businesses –protein biotherapeutics (CSL Behring) and influenza vaccines and other biologics (Seqirus) – are already among its global leaders.
Rare & Serious Diseases
We are committed to saving lives and improving the quality of life for people with rare and serious diseases worldwide. This commitment is reflected in our support of programs and activities for people with deficient or malfunctioning blood proteins that cause diseases like bleeding disorders, primary immune deficiencies and Alpha1-proteinase inhibitor deficiencies.
A continual focus on innovation in new products, improved products and manufacturing know-how is the key to future growth.
Vaccines
Seqirus is the world’s No. 2 influenza vaccine provider in sales with operations in more than 20 countries in the US$4 billion global industry. Seqirus provides a differentiated product portfolio, possesses strong pandemic and prepandemic franchises and manages one of the world’s largest influenza vaccine manufacturing networks with operations on three continents: North America, Europe and Australia.
In addition to providing influenza vaccines worldwide, Seqirus manufactures, sells and distributes a comprehensive range of vaccines, antivenoms and other pharmaceutical products in Australia and New Zealand. We also manufacture and market in vitro diagnostic products through Immunohaematology.
